S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer

Roman Nawroth(TUM Klinikum), Margitta Retz(Arbeitsgemeinschaft Urologische Onkologie)

PLoS ONE

November 15, 2011

10.1371/journal.pone.0027509

Cited by 92

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

|The Lancet|2016|3.7k

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

|The Lancet|2016|2.2k

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

|The Lancet|2017|1.4k

Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma

|Cancer Cell|2016|654

An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer

|Nature Communications|2021|381